TICKERNERD
Menu
BMRNBMRNHealthcare · Biotechnology

BMRN Stock Forecast: BioMarin Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$66
+0.26% on the day

The 27 Wall Street analysts covering BioMarin Pharmaceutical, Inc. hold a median 12-month price target of $90 — +37.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$12.7B
Ticker Nerd rank
64 / 100
Median analyst target
$90
Analysts covering
27
Revenue$989.7M+19.9% y/y
Operating income$111.0M
Net income$44.8M
Free cash flow$133.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.1%
1M
−5.6%
YTD
+10.5%
1Y
+17.5%
From 52W high
−6.5%
From 52W low
+32.2%
$50
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMRN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioMarin Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
97
Quality
87
Revisions
63
Momentum
61
Accruals
50
Growth
39
Issuance
22
Size
13

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BMRN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMRN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26BMRNHigh $124Median $90Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
20 Buy7 Hold0 Sell
Low $60Median $90High $124

The green dot is the last close — the median target sits +37.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.ReiteratesNeutral$60
1 Sept 2026Piper SandlerMaintainsOverweight$88 → $90
1 Sept 2026Piper SandlerMaintainsOverweight—
31 Aug 2026HC Wainwright & Co.MaintainsNeutral—
31 Aug 2026HC Wainwright & Co.MaintainsNeutral$59 → $60
31 Aug 2026JefferiesMaintainsBuy—
31 Aug 2026JefferiesMaintainsBuy$104 → $105
19 Aug 2026BMO CapitalInitiatesOutperform$98
19 Aug 2026BMO CapitalInitiatesOutperform—
18 Aug 2026HC Wainwright & Co.MaintainsNeutral$60 → $59
18 Aug 2026HC Wainwright & Co.MaintainsNeutral—
17 Aug 2026BarclaysMaintainsOverweight—
17 Aug 2026BarclaysMaintainsOverweight$105 → $111
17 Aug 2026Piper SandlerMaintainsOverweight$82 → $88
17 Aug 2026Piper SandlerMaintainsOverweight—
10 Aug 2026Canaccord GenuityMaintainsBuy—
10 Aug 2026Canaccord GenuityMaintainsBuy$111 → $114
7 Aug 2026HC Wainwright & Co.MaintainsNeutral$50 → $60
7 Aug 2026HC Wainwright & Co.MaintainsNeutral—
7 Aug 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMRN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BMRN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, BioMarin Pharmaceutical, Inc. returned +17.5% against +17.5% for the S&P 500, dividends included.

BMRN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26BMRNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMRN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.9%
Analysts raising
12
Analysts cutting
2
Fundamentals

BioMarin Pharmaceutical, Inc. (BMRN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
177.5×

Cheaper than 4% of US stocks

Price / sales
3.7×

Cheaper than 33% of US stocks

Price / book
2.0×

Cheaper than 45% of US stocks

EV / EBITDA
24.9×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
19.9%

Higher than 69% of US stocks

Earnings growth (YoY)
−81.4%

Higher than 5% of US stocks

Gross margin
79.5%

Higher than 90% of US stocks

Operating margin
21.2%

Higher than 80% of US stocks

Net margin
2.1%

Higher than 52% of US stocks

Returns & dividend
Return on equity
1.2%

Higher than 46% of US stocks

Return on assets
3.3%

Higher than 67% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioMarin Pharmaceutical, Inc. (BMRN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioMarin Pharmaceutical, Inc. has a market value of $12.7B and an enterprise value of $16.0B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 19.9% year on year.

  • Net income over the same four quarters: $73.0M, a 2.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.37.

  • Free cash flow in the twelve months to 30 June 2026: $725.1M.

  • Shares outstanding: 193.5M.

  • Trailing P/E: 177.5×; forward P/E: 10.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioMarin Pharmaceutical, Inc. employs 3,221 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BMRN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BMRNBioMarin Pharmaceutical, Inc.$12.7B
64
MDGLMadrigal Pharmaceuticals, Inc.$12.3B
69
HALOHalozyme Therapeutics, Inc.$12.2B
97
CORTCorcept Therapeutics, Inc.$12.1B
79
ARWRArrowhead Pharmaceuticals, Inc.$11.6B
57
SMMTSummit Therapeutics, Inc.$14.0B
21
BBIOBridgeBio Pharma, Inc.$14.0B
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioMarin Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BMRN news & analysis

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

BioMarin Pharmaceutical presented at Citigroup's Biopharma Back to School Summit 2026, and a transcript of the presentation was published on Seeking Alpha. The item serves as an announcement of the company's participation in the conference.

Why it matters — A BioMarin watcher would care because the published transcript offers insight into the company's management commentary and messaging delivered to investors at a major industry conference.

BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

BioMarin Pharmaceutical presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item covers the company's remarks at the investor conference.

Why it matters — A BMRN watcher would care because the conference transcript offers insight into the company's latest strategic commentary and business updates directly from management.

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

PRNewsWire · 9 Sept 2026positive

BioMarin announced that positive Phase 3 CANOPY-HCH-3 data for VOXZOGO (vosoritide) in children with hypochondroplasia were published in NEJM Evidence and presented at the ESPE 2026 Annual Meeting. The study showed statistically significant improvements across multiple growth measures, and BioMarin has submitted a supplemental New Drug Application to the FDA to expand VOXZOGO to include children with hypochondroplasia.

Why it matters — The publication of positive Phase 3 data and the FDA sNDA submission could expand VOXZOGO's approved use to a broader pediatric patient population, potentially widening the drug's market opportunity for BioMarin.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

Zacks Investment Research · 3 Sept 2026positive

BioMarin has converted a competitive threat into a royalty-bearing asset, as Ascendis will pay royalties on Yuviwel sales. This arrangement reshapes the economics of the competition in BioMarin's favor.

Why it matters — A BMRN watcher would care because the company has turned a potential market competitor into a source of recurring royalty income rather than a direct headwind.

FAQ

Frequently asked questions about BMRN stock

What is the BMRN stock price forecast for 2026-2027?

The 27 Wall Street analysts covering BioMarin Pharmaceutical, Inc. have a median 12-month price target of $90, with estimates ranging from $60 to $124. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMRN stock a buy right now?

Of the 27 analysts covering BioMarin Pharmaceutical, Inc., 20 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioMarin Pharmaceutical, Inc. 64 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMRN?

As at 12 Sept 2026, BioMarin Pharmaceutical, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will BMRN stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +37.0% from the last close, and Ticker Nerd's factor model ranks BioMarin Pharmaceutical, Inc. 64 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMRN stock forecast for 2030?

No analyst covering BioMarin Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $124 over the next 12 months.

How has BMRN stock performed over the past year?

BioMarin Pharmaceutical, Inc. returned +17.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioMarin Pharmaceutical, Inc. do?

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases.

What is the latest news on BMRN?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". BioMarin Pharmaceutical presented at Citigroup's Biopharma Back to School Summit 2026, and a transcript of the presentation was published on Seeking Alpha. The item serves as an announcement of the company's participation in the conference.

Company

About BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.

CEO Mr. Alexander Hardy · 3,221 employees · United States · https://www.biomarin.com